Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, Systemic Immune Inflammation Index and Efficacy of Remote Ischemic Conditioning in Acute Ischemic Stroke: A Post Hoc Exploratory Analysis of the RICAMIS Study
Qi Wang,Wen-Na Li,Wuxiyar Otkur,Yu Cui,Hui-Sheng Chen
DOI: https://doi.org/10.2147/jir.s460928
IF: 4.5
2024-08-21
Journal of Inflammation Research
Abstract:Qi Wang, 1, 2, &ast Wen-Na Li, 3, &ast Wuxiyar Otkur, 4 Yu Cui, 1 Hui-Sheng Chen 1, 2 1 Department of Neurology, General Hospital of Northern Theater Command, Shenyang, 110016, People's Republic of China; 2 Dalian Medical University, Dalian, People's Republic of China; 3 Department of Neurology, Tangshan Central Hospital, Tangshan, People's Republic of China; 4 School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hui-Sheng Chen, Department of Neurology, General Hospital of Northern Theater Command, 83 Wen Hua Road, Shenyang, 110016, People's Republic of China, Tel +86 024 28897511, Email Background: We conducted a post-hoc analysis of the RICAMIS trial to investigate the effect of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) on the efficacy of remote ischemic conditioning treatment. Methods: In this post-hoc analysis, NLR, PLR, and SII were measured before randomization. Patients were divided into two groups based on their cut-off values: high vs low NLR, high vs low PLR, and high vs low SII groups. Each group was further subdivided into RIC and control groups. The primary endpoint was a poor outcome (mRS 2– 6 at 90 days). Differences in the primary endpoint between the RIC and control subgroups were compared, and the interactions of treatment assignment with NLR, PLR, and SII were evaluated. Results: A total of 1679 patients were included in the final analysis. Compared with the control group, RIC significantly improved functional outcomes regardless of the inflammation status. The improved probability of poor outcome in the RIC vs control group was numerically greater in the high vs low inflammation group (NLR, 7.8% vs 5.1%; PLR, 7% vs 6.5%; SII, 9% vs 5.3%). However, we did not find an interaction effect of an intervention (RIC or control) with different NLR, PLR, or SII on clinical outcomes (P > 0.05). In addition, the NLR and SII were independently associated with functional outcomes in all patients, regardless of whether they received RIC. Conclusion: Inflammation may not affect the efficacy of RIC in patients with acute moderate ischemic stroke, although a lower probability of poor outcome at 90 days was identified in patients with a high vs low inflammatory status. Keywords: neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, remote ischemic conditioning, ischemic stroke As a non-pharmacological treatment, the neuroprotective effect of remote ischemic conditioning (RIC), intermittently blocking the blood flow of limbs and producing transient ischemic with the intention of protecting brain, on ischemic stroke has been widely investigated in preclinical and clinical studies, and the results suggested that its potential benefit through multiple neuroprotective mechanisms. 1–5 Our recent remote ischemic conditioning for acute moderate ischemic stroke (RICAMIS) trial provided the first robust evidence for the benefit of RIC in acute moderate ischemic stroke, 6 but the patient who will benefit the most from RIC intervention has not been identified, which is an important concern in clinical practice. Growing evidence suggests a key role of the inflammatory response in ischemic stroke, involving the entire process of its development, progression and repair. 7–11 Preclinical studies have shown that the neuroprotective effect of RIC intervention is mediated by anti-inflammatory effects. 12–16 The inflammatory response is orchestrated by numerous immune cells, such as lymphocytes, granulocytes, and monocytes, and the cell counts of these immune cells provide vital information on inflammatory statuses. 8,10 Recently, several low-priced easy-to-measure white blood cell-based inflammatory indicators have been introduced, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII), 17–21 which have been found to be positively correlated with poor functional outcome of acute ischemic stroke. 22,23 However, the effects of these inflammatory indicators on the efficacy of RIC interventions have not been investigated. Therefore, we performed an exploratory post hoc analysis of the RICAMIS trial to investigate the effects of the NLR, PLR, and SII on the efficacy of RIC treatment. Details of the design, protocol, and statistical analysis plan of RICAMIS have been published. 6 In -Abstract Truncated-
immunology